Stomach Cancer Treatment

A Global Strategic Business Report

MCP33058

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

6954

EXECUTIVE POOL

5850

PRICE

818

EXPERT INPUTS

44

COMPANIES

297

DATA TABLES

371

PAGES

2

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (55)

3

CXO

5

VICE PRESIDENT

10

DIRECTOR

25

MANAGER

12

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Stomach Cancer Treatment Market to Reach US$10.4 Billion by 2030

The global market for Stomach Cancer Treatment estimated at US$5.2 Billion in the year 2024, is expected to reach US$10.4 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2024-2030. Standard Chemotherapy, one of the segments analyzed in the report, is expected to record a 13.6% CAGR and reach US$7.0 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 16.6% CAGR

The Stomach Cancer Treatment market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.7% and 10.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.7% CAGR.

Global Stomach Cancer Treatment Market – Key Trends & Drivers Summarized

Why Is Stomach Cancer Treatment Receiving Renewed Global Focus Across Healthcare Systems?

Stomach cancer, or gastric cancer, remains one of the leading causes of cancer-related mortality worldwide, particularly in East Asia, Eastern Europe, and parts of Latin America. While overall incidence is declining in some regions due to improved food safety, Helicobacter pylori eradication, and early screening efforts, it continues to pose a significant health challenge due to late-stage diagnosis and limited treatment accessibility in many countries. The global healthcare community is shifting its focus toward stomach cancer due to rising awareness, expanded screening initiatives, and improvements in data collection that underscore the disease`s true burden. In high-risk countries such as Japan, South Korea, and China, organized screening programs are detecting more cases at an earlier, potentially curable stage—driving a surge in demand for curative surgical and pharmacologic interventions. In the West, where stomach cancer tends to present at more advanced stages, there is growing clinical attention on novel systemic therapies that can extend survival and improve quality of life. This renewed focus is pushing pharmaceutical innovation, health system planning, and academic research into more coordinated, strategic efforts to manage and eventually reduce stomach cancer mortality on a global scale.

How Are Targeted Therapies and Immuno-Oncology Redefining the Treatment Landscape?

The stomach cancer treatment landscape is undergoing a major transformation fueled by advances in precision medicine, biomarker testing, and immunotherapy. Traditionally treated with surgery, chemotherapy, and radiation, stomach cancer is now being managed with more tailored approaches that consider molecular subtypes, genetic mutations, and PD-L1 expression levels. HER2-targeted therapies, such as trastuzumab, have significantly improved outcomes for patients with HER2-positive gastric cancer, while new antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors are expanding the arsenal against other oncogenic drivers. Immune checkpoint inhibitors like pembrolizumab and nivolumab have shown promising results in patients with advanced or metastatic gastric cancer, particularly in those with high microsatellite instability (MSI-H) or elevated tumor mutational burden (TMB). Combination therapies—pairing immunotherapy with chemotherapy or anti-angiogenic agents—are being explored to overcome resistance and improve response durability. Liquid biopsies and next-generation sequencing are facilitating earlier and more accurate treatment selection, ushering in an era of personalized care for stomach cancer patients. As regulatory approvals accelerate and clinical trial pipelines deepen, these therapeutic advances are expected to significantly reshape the standard of care in both first-line and refractory settings.

Where Is Market Demand Expanding, and Which Patient Populations Are Driving Treatment Needs?

Market demand for stomach cancer treatment is rising globally, with the highest patient burden concentrated in Asia-Pacific countries such as China, Japan, and South Korea, which account for over half of the world’s cases. These regions are characterized by proactive screening policies, strong government support, and well-established treatment protocols, making them hotspots for both early intervention and pharmaceutical sales. In Western countries, including the United States, Germany, and the UK, although incidence is comparatively lower, a shift toward younger-onset gastric cancer cases and high rates of advanced-stage presentation are intensifying treatment demands. Latin America, Eastern Europe, and parts of Africa are experiencing growing prevalence but face challenges related to late detection, treatment infrastructure, and drug access—highlighting opportunities for generic chemotherapy agents, biosimilars, and public health partnerships. Elderly patients, who account for a large proportion of new diagnoses, are driving demand for less toxic, more tolerable regimens, while younger patients are prompting interest in fertility-sparing treatments and long-term survivorship planning. Urbanization, dietary shifts, and persistent H. pylori infection in developing regions are also contributing to a steady expansion in the treatment-eligible population, creating pressure on healthcare systems to provide timely, effective, and affordable care.

What’s Driving the Long-term Growth of the Stomach Cancer Treatment Market Globally?

The growth in the stomach cancer treatment market is driven by a confluence of demographic trends, evolving therapeutic options, policy frameworks, and diagnostic advancements. A primary long-term driver is the aging global population, which is increasing the baseline risk for stomach cancer and expanding the pool of patients needing treatment. Advances in molecular profiling and companion diagnostics are enabling oncologists to move away from “one-size-fits-all” chemotherapy to precision-based regimens that target specific tumor biology—improving efficacy and minimizing side effects. The global expansion of cancer immunotherapy is opening new treatment windows for advanced or previously intractable cases. Governments and health organizations are investing in cancer control programs that prioritize early detection and access to care, while pharmaceutical companies are responding with intensified R&D investment, particularly in combination therapies and next-gen biologics. In parallel, emerging markets are building oncology infrastructure and reforming drug reimbursement policies, broadening access to both established and novel therapies. The increasing role of tele-oncology, electronic health records, and global clinical trial collaboration is also enhancing patient management and data-driven treatment optimization. As scientific understanding of gastric cancer deepens and therapeutic innovations continue to emerge, the stomach cancer treatment market is poised for sustained growth—anchored by its crucial role in addressing one of the world’s most aggressive and underdiagnosed malignancies.

SCOPE OF STUDY

The report analyzes the Stomach Cancer Treatment market by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Standard Chemotherapy, Targeted Therapy, Immunotherapy); Disease Indication (Gastric Cancer / Gastroesophageal Junction cancer, Gastrointestinal Stromal Tumors); Administration Route (Oral, Injectable).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa..

SELECT PLAYERS

Amgen Inc.; Astellas Pharma Inc.; AstraZeneca PLC; Bayer AG; BeiGene, Ltd.; Bristol-Myers Squibb Company; CELLTRION INC.; Daiichi Sankyo Company, Limited; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GSK plc; Harbour BioMed; Imugene Limited; Innovent Biologics, Inc.; Ipsen Pharma; Jiangsu Hengrui Medicine Co., Ltd.; Merck & Co., Inc.; Mirxes; Mylan N.V.; Myriad Genetics, Inc.; Novartis AG; Otsuka Holdings Co., Ltd.; Pfizer Inc.; Samsung Bioepis; Sanofi S.A.; TAIHO PHARMACEUTICAL CO., LTD.; Teva Pharmaceutical Industries Ltd.; Triumvira Immunologics; WMT AG;

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy

How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind

Stomach Cancer Treatment – Global Key Competitors Percentage Market Share in 2025 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 44 Players Worldwide in 2025 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Global Incidence of Gastric Cancer Throws the Spotlight on the Urgent Need for Targeted and Multimodal Treatment Approaches

Surge in Demand for Precision Oncology Spurs Growth in HER2-positive and MSI-high Targeted Therapies for Stomach Cancer

Here`s How the Integration of Immunotherapy Expands the Addressable Market Beyond Traditional Chemotherapy Protocols

Advancements in Biomarker Testing and Genomic Profiling Strengthen the Business Case for Personalized Gastric Cancer Care

Here`s the Story: Early-stage Diagnosis Rates Remain Low, Driving Innovation in Neoadjuvant and Adjuvant Treatment Strategies

Growing Pipeline of Immune Checkpoint Inhibitors and Anti-angiogenesis Agents Fuels Novel Treatment Combinations

Increased Adoption of Minimally Invasive Surgery and Robotic-assisted Resection Enhances Curative Outcomes in Eligible Patients

Expansion of Targeted Therapy Access in Emerging Markets Unlocks Commercial Opportunities for Biosimilars and Biologics

Growth of Tele-oncology and Remote Monitoring Tools Enhances Continuity of Gastric Cancer Treatment in Underserved Areas

Manufacturing Innovation and Cold Chain Optimization Sustain Global Supply of Injectable and Infusible Oncology Products

4. GLOBAL MARKET PERSPECTIVE

World Stomach Cancer Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

World Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Stomach Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Standard Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Standard Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Standard Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Gastric Cancer / Gastroesophageal Junction cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Gastric Cancer / Gastroesophageal Junction cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Gastric Cancer / Gastroesophageal Junction cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Gastrointestinal Stromal Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Gastrointestinal Stromal Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Gastrointestinal Stromal Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

USA Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

USA Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

JAPAN

Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

CHINA

Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

China Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

China Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

EUROPE

Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Europe Historic Review for Stomach Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

FRANCE

Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

France Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

France Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

GERMANY

Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

UNITED KINGDOM

Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

UK Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

UK Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

SPAIN

Spain Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Spain 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Spain Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Spain 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Spain Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Spain 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

RUSSIA

Russia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Russia 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Russia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Russia 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Russia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Russia 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

ASIA-PACIFIC

Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Stomach Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

AUSTRALIA

Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)

Australia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Australia 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Australia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Australia 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Australia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Australia 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

INDIA

Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)

India Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

India Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

India 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

India Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

India Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

India 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

India Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

India Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

India 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

SOUTH KOREA

South Korea Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

South Korea 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

South Korea Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

South Korea 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

South Korea Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

South Korea 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

REST OF ASIA-PACIFIC

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

LATIN AMERICA

Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)

Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Latin America Historic Review for Stomach Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

ARGENTINA

Argentina Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Argentina 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Argentina Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Argentina 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Argentina Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Argentina 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

BRAZIL

Brazil Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Brazil 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Brazil Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Brazil 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Brazil Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Brazil 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

MEXICO

Mexico Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Mexico 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Mexico Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Mexico 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Mexico Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Mexico 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

REST OF LATIN AMERICA

Rest of Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Latin America 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Rest of Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Latin America 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Rest of Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Latin America 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

MIDDLE EAST

Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)

Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Middle East Historic Review for Stomach Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

IRAN

Iran Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Iran 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Iran Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Iran 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Iran Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Iran 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

ISRAEL

Israel Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Israel 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Israel Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Israel 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Israel Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Israel 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

SAUDI ARABIA

Saudi Arabia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Saudi Arabia 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Saudi Arabia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Saudi Arabia 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Saudi Arabia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Saudi Arabia 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

UNITED ARAB EMIRATES

UAE Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UAE 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

UAE Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UAE 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

UAE Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UAE 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

REST OF MIDDLE EAST

Rest of Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Middle East 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Rest of Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Middle East 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Rest of Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Middle East 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

AFRICA

Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)

Africa Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Africa 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030

Africa Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Africa 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030

Africa Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Africa 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
Florida Cancer Specialists	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll